Clinical Trials

Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.

 

Lung & Thoracic Cancer Trials

  • STUDY10485

    A Phase 1, Open Label, Dose Escalation and Cohort Expansion First in Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti LAG 3 mAb) Administered Alone or in Combination with REGN2810 (anti PD 1 mAb) in Patients with Advanced Malignancies

    To evaluate safety and PK in order to determine an RP2D of REGN3767 as monotherapy and in combination with REGN2810 in patients with advanced malignancies, including lymphoma. To assess preliminary anti-tumor activity of REGN3767 alone and in combination with REGN2810 (separately by cohort) as measured by ORR.

    Study Information



  • STUDY8700

    Molecular Analysis for Therapy Choice (MATCH)

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.

    Study Information



  • STUDY8081

    A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

    To evaluate whether adjuvant therapy with crizotinib will result in improved overall survival (OS) over placebo for patients with stage IB ? 4cm, II and IIIA, ALK-positive NSCLC following surgical resection.

    Study Information



  • STUDY12244

    A PHASE 3, OPEN LABEL, 3 COHORT RANDOMIZED STUDY OF N 803 IN COMBINATION WITH CURRENT STANDARD OF CARE VS STANDARD OF CARE AS FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)

    This is a phase 2, open-label, randomized study to compare the safety and efficacy of combination therapy with ALT-803 and pembrolizumab (experimental arm) versus pembrolizumab alone (control arm), as first-line treatment for subjects with metastatic NSCLC in which pembrolizumab is indicated for first-line treatment.

    Study Information



  • STUDY13542

    A Phase 1/2 Dose Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    This is a multicenter, Phase 1a/1b, study consisting of 2 parts, with Part 1 the Phase 1a portion of the study and Part 2 the Phase 1b portion. The aim of the study is to evaluate the safety and tolerability, as well as to obtain preliminary evidence of antitumor activity and anti-CACS activity, of NGM120 monotherapy in subjects with select advanced solid tumors (Part 1) and of NGM120 in combination with gemcitabine and Abraxane for the management of metastatic pancreatic cancer (Part 2). Part 2 will start at the same time as Part 1 and run concurrently.

    Study Information